Economic burden of breast cancer in Chinese women: analysis o from 2016 to 2018 using national health insurance data
Economic burden of breast cancer in Chinese women: analysis o from 2016 to 2018 using national health insurance data
Blog Article
Background: In 2022, there were approximately 19.96 million new cancer cases globally according to GLOBOCAN, with breast cancer emerging as the most commonly diagnosed female cancer.In China, there were 0.36 million new cases and 75,000 deaths due to breast cancer of women in 2022.
However, studies focusing on the cost of treatment and the economic burden of female breast cancer patients in China were conducted within specific provinces, cities, or hospitals, and there lacks a comprehensive analysis of total treatment cost.This study aimed to analyze the costs associated with female breast cancer patients in China using data from the China Health Insurance Research Association (CHIRA) and to explore the factors influencing costs.Methods: Female breast cancer patients read more aged over 16 years were included in the CHIRA database between 2016 and 2018.Patients were identified according to ICD-10 code.
Descriptive analysis and log-linear analysis were conducted to examine the treatments of breast cancer.The project was commissioned with an ethical exemption.Findings: A total of 28,464 breast cancer patients aged 16 years and older who were diagnosed with breast cancer in China between January 2016 and December 2018 were included in this study.The mean age of 54.
49 years, and the highest proportion of breast cancer patients were aged 50-60 years (30.66%).Approximately 72.54% of patients were covered by Urban Employee Basic Medical Insurance (EBMI).
In this study, 73.56% of breast cancer patients utilized inpatient services, although, this study found the proportion of patients seeking medical treatment in lower-level hospitals increased over time, over 82.07% of the study population still seek care at tertiary hospitals in China.The cost of treatment decreased with increasing age and increased among patients treated at higher-level hospitals.
Age, health insurance type, region, and hospital level were found to be associated with both total medical costs and out-of-pocket expenses for breast cancer patients.The annual total medical cost per capita decreased for outpatients and increased for inpatients over the three years.Inequities have been identified in financial protection for patients covered by different health insurance schemes and in different regions.Interpretation: The costs of breast cancer patients bovi-shield gold fp 5 l5 in China exhibit significant regional and demographic differences, with Chinese patients being significantly younger compared to those in other countries.
Efforts in expanding breast cancer screening are necessary to reduce the disease severity and financial burden.Considering the variance in quality of care across different levels of hospitals, efforts should also be made to enhance the quality of care for cancer treatment in lower-level hospitals, and to ensure favorable health outcomes for patients.Funding: This study was funded by National Key Research and Development Program of China, National Natural Science Foundation of China, China Medical Board, the Royal Society.